Australian pharma firm Genetic Signatures gains as Bell Potter lifts PT
** Shares of Australia's Genetic Signatures GSS.AX rise as
much as 6.2% to A$0.78, their highest since early June
** Analysts at Bell Potter raise PT on the pharmaceutical
company to A$1.1 from A$0.75; keep stock rating at "Buy"
** Brokerage says FY25 set to be positive year for the
drugmaker post appointment of "experienced" CEO
** Bell Potter highlights strength of co's improved balanced
sheet post recent capital raise
** Stock has risen 67.8% this year as of last close
(Reporting by Rishav Chatterjee in Bengaluru)
((Rishav.Chatterjee@thomsonreuters.com;))
Recent news on Genetic Signatures
See all newsBrief: Genetic Signatures Says Microba Shareholders To Hold 60% Of GSS On Merger
Australia's Genetic Signatures urges largest stakeholder to clarify merger intentions; shares rise
Brief: Genetic Signatures Receives Request From BCAL Diagnostics To Call General Meeting Of Shareholders
Brief: Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
Brief: Genetic Signatures Announces Board Changes